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Abstract
Multiple sclerosis (MS) is an inflammatory, demyelinating, and neurodegenerative disease of the central nervous system
(CNS) triggered by autoimmune mechanisms. Microglia are critical for the clearance of myelin debris in areas of demyelination, a key step to allow remyelination. TREM2 is expressed by microglia and promotes microglial survival, proliferation,
and phagocytic activity. Herein we demonstrate that TREM2 was highly expressed on myelin-laden phagocytes in active
demyelinating lesions in the CNS of subjects with MS. In gene expression studies, macrophages from subjects with TREM2
genetic deficiency displayed a defect in phagocytic pathways. Treatment with a new TREM2 agonistic antibody promoted the
clearance of myelin debris in the cuprizone model of CNS demyelination. Effects included enhancement of myelin uptake
and degradation, resulting in accelerated myelin debris removal by microglia. Most importantly, antibody-dependent TREM2
activation on microglia increased density of oligodendrocyte precursors in areas of demyelination, as well as the formation
of mature oligodendrocytes thus enhancing remyelination and axonal integrity. These results are relevant as they propose
TREM2 on microglia as a potential new target to promote remyelination.

Introduction

Francesca Cignarella and Fabia Filipello contributed equally.
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s00401-020-02193-z) contains
supplementary material, which is available to authorized users.

Multiple sclerosis (MS) is a chronic demyelinating disease
of the central nervous system (CNS), whose pathogenesis
involves inflammatory and neurodegenerative processes.
Current MS immunomodulatory treatments target CNS
inflammation, while therapies capable of regenerating
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myelin and halting disease progression are lacking [28].
Oligodendrocyte precursor cells (OPCs) are multipotent
progenitor cells widely distributed in the CNS that could
differentiate into mature oligodendrocytes (OLs) to sustain
remyelination. In MS, impaired generation of OLs from
OPCs leads to persistent demyelination, myelin debris accumulation, and axonal damage which clinically manifests as
neurological disability [11]. Efficient myelin debris removal
and clearance by phagocytic cells are critical to eliminate
inhibitory signals interfering with OPC activation, recruitment to the site of demyelination and/or differentiation into
myelinating mature OLs [14, 26, 27].
Microglial cells and infiltrating monocytes/macrophages
can have a dual role in MS lesions. They could contribute to myelin damage and lesion expansion, or they may
have a protective role by clearing myelin debris, reducing
inflammation and secreting regenerative factors promoting
remyelination [48]. A critical modulator of microglia functions is the triggering receptor expressed on myeloid cells-2
(TREM2), an innate immune receptor expressed by several
myeloid cells including brain microglia [23, 45]. TREM2 is
a phospholipid sensing receptor known to sustain microglial
cell activation and expansion in response to demyelination
or amyloid plaques in Alzheimer’s disease (AD) [8, 42, 50].
Recently, TREM2 was proposed to be a key transcriptional
regulator of cholesterol metabolism during chronic phagocytic activity for myelin clearance in response to demyelination [35].
TREM2 binds on the membrane to the DNAX-activation
protein 12 (DAP12) which is an adaptor protein required for
TREM2 surface expression and intracellular signaling [47].
TREM2 engagement leads to DAP12 phosphorylation, followed by recruitment and activation of the spleen-associated
tyrosine kinase (SYK), resulting in downstream signaling
events leading to proliferation, survival, phagocytosis, and
secretion of cytokines and chemokines [47]. Homozygous
loss-of-function mutations in TREM2 or DAP12 genes cause
Nasu–Hakola disease (NHD), a rare genetic disorder characterized by fatal presenile dementia and bone cysts [38, 39].
Neuropathological findings in NHD include loss of myelin
and axons in the brain, with reactive astrocytosis and microglial activation [25]. Heterozygous TREM2 gene variants
were reported to increase the risk for AD and other neurodegenerative diseases (frontotemporal dementia, Parkinson’s
disease and amyotrophic lateral sclerosis) [7, 16, 20, 43].
Here, we explored the effect of antibody-mediated
TREM2 activation on microglia in a well-established toxininduced model of demyelination in the CNS resulting from
exposure to the copper chelator cuprizone (CPZ) in the diet
[31]. In this model, oligodendrocyte degeneration in the
brain is followed by a robust microglial response consisting
of activation, proliferation and clearance of myelin debris
[17]. These events lead to OPC recruitment, differentiation
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into mature OLs, and then remyelination which is almost
complete within few weeks from toxin withdrawal [31]. We
show that treatment with a TREM2-agonistic antibody was
able to enhance myelin debris clearance by microglia in vivo
in the CPZ-model and by bone marrow-derived macrophages
(BMDM) in vitro. Most importantly, these events resulted in
increased OPC recruitment and differentiation into mature
OLs eventually accelerating remyelination in vivo and preserving axonal health. This provides the proof of concept
that antibody-mediated TREM2 activation could promote
remyelination, suggesting this as a potential novel therapeutic avenue in MS and other demyelinating disorders.

Materials and methods
Mice
Trem2+/+, Trem2+/,−and Trem2−/− mice (backcrossed 12 generations to the C57BL/6 background) were obtained from
Professor Marco Colonna (Washington University in St.
Louis). These three strains were bred in parallel. Animals
were housed in accordance with University and National
Institutes of Health (NIH) guidelines, and animal protocols
were approved by the Washington University Animal Studies Committee (study approval number: 20180056). Mice
were maintained under controlled conditions (19–22 °C and
a in a 12-h light/dark cycle with unrestricted access to food
and water). Experiments performed by Alector (Fig. 2 and
Supplementary Fig. 1a and c) used the Trem2−/− mouse colony originally generated by the trans-NIH KnockOut Mouse
Project (KOMP). Frozen sperms were obtained from the UC
Davis KOMP repository, and a colony of mice was established at UC Davis.

Antibody generation
Monoclonal antibodies targeting mouse TREM2 were generated by immunizing mice genetically deficient of TREM2
(Trem2−/−) with recombinant TREM2 protein and hybridoma generation, as well as by a yeast display campaign
(performed by Adimab). AL002a was screened for TREM2
specificity by selecting for binding to wild-type (Trem2+/+),
but not Trem2−/− BMDM.

Mouse model of CPZ‑induced demyelination
Six- to eight-week-old Trem2 +/+ , Trem2 +/− , and
Trem2−/− mice were fed a 0.2% Bis-(cyclohexanone) oxaldihydrazone (cuprizone) diet (5C5N: Modified PicoLab®
Rodent w/0.2% Cuprizone, TestDiet. Cuprizone from Alpha
Aesar, A10628) for 4 weeks (WK 4) or for 4 weeks followed
by 3 days (WK 4 + 3D), 7 days (WK 4 + 7D), or 14 days
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(WK 4 + 14D) on regular chow (PicoLab Rodent Diet 20
#5053, Purina). For the full duration of the experiment mice
were injected intraperitoneally (i.p.) once a week with the
anti-TREM2 antibody or the control antibody at a dose of
80 mg/kg. The first injection with the antibodies was performed 4 days before beginning the CPZ-diet.

Quantification of antibody levels in the brain
Six- to eight-week-old Trem2+/− mice were injected i.p. with
AL002a. 48 h post injection, brains were removed after perfusion with PBS, micro-dissected to isolate the corpus callosum (CC) and the cortex (Ctx), and immediately frozen
in liquid nitrogen. Tissues were solubilized in N-Per lysis
buffer (87792, ThermoFisher) and cell protein content was
measured using the Pierce bicinchoninic acid (BCA) protein
assay kit (23227, Thermo Scientific). A mouse Trem-2b/Fc
Chimera (R&D Systems) was used as a capture antibody and
coated overnight at 4 °C on 96-well Meso Scale Discovery
(MSD) plates in PBS. After washing, wells were blocked for
1 h at 37 °C with binding buffer (3% BSA in PBS). Titration
of samples and standards were incubated for 1 h at room
temperature (RT) on a shaker at 500 rpm. For detection
(0.5 mg/ml) of Sulfo-TAG goat anti-mouse IgG (MSD) were
added to the plate. After washing, read buffer was added and
the plate was read on the Sector Imager. Washes between
the different steps were done three times with 0.05% Tween
20 in PBS. Antibody content was normalized to serum and
protein content.

Bone marrow‑derived macrophages
Bone marrow-derived macrophages (BMDM) were obtained
by flushing tibial and femoral marrow cells with cold PBS
2% FBS. Red blood cells were lysed using ACK lysing
buffer (Thermo Fisher), and after two washes in PBS 2%
FBS, the cells were re-suspended in complete media (RPMI,
10% FBS, Pen/Strep, l-glutamine, non-essential amino acid)
with (50 ng/ml) murine M-CSF (m-M-CSF) to obtain differentiated macrophages after 6 days. Adherent macrophages
were detached with 1 mM EDTA in PBS.

Immunoprecipitation
Immunoprecipitation in vitro: before stimulation, BMDM
were starved for 4 h in RPMI with 1% FBS. 10 × 106 cells
were incubated for 15 min at 4 °C with AL002a or control antibody (1 µg for 1 06 cells). Cells were then washed
and incubated at 37 °C in the presence of goat-anti mouse
IgG (1.5 µg for 1 × 106 cells). After stimulation, cells were
lysed with lysis buffer (1% n-dodecyl-β-d-Maltoside, 50 Mm
Tris–HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1.5 mM
MgCl2, 10% glycerol, protease, and phosphatase inhibitors)
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and immunoprecipitated with an anti-TREM2 antibody
that binds a different domain (rat anti-h/m-TREM2, clone
237920, R&D system). Immunoprecipitation in vivo: 6- to
8-week-old C57BL/6 mice were injected i.p. with 3 ml of
3% thioglycollate. After 3 days, when the peritoneal cavity
was enriched with C
 D11b+F4/80+ macrophages expressing
TREM2, mice were injected with control or TREM2-specific antibodies (40 mg/kg). 24 h after antibody injection,
peritoneal macrophages were collected, immediately lysed
in the lysis buffer previously described, and immunoprecipitated with rat anti-h/m TREM2 antibody described above
(R&D System, clone 237920). Then, for both in vitro and
in vivo experiments, precipitated proteins were fractionated
by SDS-PAGE in non-reducing conditions, transferred to
PVDF membranes, and probed with an anti-phosphotyrosine
antibody (4G10, Millipore). TREM2 is not detected in nonreducing condition. To confirm that all substrates were adequately immunoprecipitated, whole cell lysates from each
sample were also fractionated by SDS-PAGE in reducing
condition and immunoblotted with an anti-actin antibody
(actin, sc-47778 Santa Cruz).

Myelin production
Human myelin was prepared as previously described [34]
and stored in lyophilized form at − 80 °C. Prior to use,
myelin was suspended in DMEM to a final concentration of
(2 mg/ml) and dissolved by vortexing and sonicating. Myelin
was then irradiated with 10,000 RADS to achieve sterility.
Aliquots were stored at − 80 °C for further use.

NFAT‑Luciferase reporter assay
A stable BW5147.G.1.4 (ATCC® TIB48™) (BWZ) cell line
expressing both mouse TREM2 and DAP12 was generously
provided by the Seaman lab [10]. This line was infected
with a Cignal PLenti NFAT-Luciferase virus (Qiagen) to
generate a stable mouse TREM2 reporter cell line, able to
induce luciferase signaling upon TREM2 activation. The
activity of the reporter was validated using PMA (0.05 μg/
ml) and ionomycin (0.25 μM). To test whether TREM2
antibody induced signaling, 5 µg/ml of soluble AL002a,
or control antibody was added to each well of 96-well culture plates together with 100,000 cell/well and incubated
for 4–6 h at 37 °C in Dulbecco’s Modified Eagle Medium
(DMEM). Luciferase activity was measured by removing
media and adding 50 μl of PBS and 50 μl of OneGlo Reagent
(Promega) to each well and incubating for 3 min at room
temperature on a plate shaker to lyse the cells. Luciferase
signal was measured using a BioTek plate reader. Data were
analyzed using GraphPad Prism.
To test myelin-induced signaling, human myelin was
diluted in PBS to 200 µg/ml, titrated onto a 96-well tissue
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culture plate, and incubated overnight at 4 °C. The next
morning, the solution was removed, and plates were washed
three times with 200 µl PBS. Plates were air dried and BWZ
cells (with or without antibodies) were added, incubated, and
analyzed as described above.

Myelin phagocytosis and degradation assays
BMDM obtained from Trem2+/− mice were seeded in 8-well
chamber slides (35,000 cells/well) (154534 Nunc, Lab-Tek)
in normal medium as described before. After 1 day, media
was substituted with reduced FBS media (5% FBS) and
macrophages were pre-incubated with AL002a or control
antibody (10 µg/ml) 3 h before starting the experiments. For
phagocytosis assays, BMDM were incubated with human
myelin (20 µg/ml) for 30 min, 1 h, or 3 h, and after incubation, cells were washed in PBS and fixed in 4% PFA. For
degradation assays, BMDM were incubated with human
myelin (20 µg/ml) for 2 h, then washed thoroughly with
PBS, and again put in culture in reduced FBS media. Cells
were left in culture for 1 h, 24 h, or 48 h, then washed in
PBS, and fixed in 4% PFA. For intracellular staining, cells
were permeabilized and blocked for 60 min at RT in 5%
horse serum and 0.1% saponin in PBS, and incubated at 4 °C
overnight with primary antibodies Rt anti-MBP (Abcam,
ab7349, 1:100) and Gt anti-Iba1 (Novus, NB100-1028,
1:250) diluted in PBS and 5% horse serum.

Mouse tissue processing and histological analyses
Mice were perfused with 4% paraformaldehyde. Mouse
brains were removed and post-fixed in 4% PFA for 24 h, followed by immersion in 30% sucrose for 48 h, then embedded
in Optimal Cutting Temperature (OCT). 5-μm sections were
placed on glass slides and stained with solochrome cyanine
to confirm the presence of a lesion as previously described
[22]. Sections were stained with the following primary
antibodies: Rb anti-dMBP (Millipore, ab5864, 1:2000), Rb
anti-Iba1 (Wako, 019-19741, 1:600), Gt anti-Iba1 (Novus,
NB100-1028, 1:250), Rt anti-LAMP1 (Abcam, ab25245,
1:500), Rt anti-CD68 (Invitrogen, 14-0681-82, 1:300),
Rb anti-PDGFRα (ThermoFisher, PA5-16742, 1:50), Rb
anti-OLIG2 (Milipore, AB9610, 1:300), Ms anti-CNPase
(Abcam, ab6319, :100), Shp anti-BrdU (Abcam, ab1893,
1:250), Rt anti-GFAP (ThermoFisher, 13-0300, 1:200), and
Ms anti-SMI-31 (Biolegend, 801603, 1:1000). AlexaFluorconjugated secondary antibodies (Invitrogen, 1:1000) were
used. Some of the images were acquired with a Nikon
Eclipse 90i fluorescent and bright field microscope equipped
with 10 × and 20 × zoom objectives and analyzed with
Metamorph 7.7 software. CNPase, dMBP, and GFAP were
analyzed as the percentage area of positive staining (number of positive pixels/mm2) within the region of interest.
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Iba1, PDGFRα, BrdU, and OLIG2 were quantified as the
density of cells in the region of interest (number of cells/
mm2). LAMP1 and CD68 were analyzed as the percentage
area of LAMP1+Iba1+ and CD68+Iba1+ staining (number of
positive pixels/mm2) and then normalized on the percentage
of Iba1+ staining (number of positive pixels/mm2) within
the region of interest. For confocal analysis, images were
acquired with an Olympus FV1200 laser scanning confocal microscope (Olympus-America Inc., Waltham, MA)
equipped with a PlanApoN 60 ×, 1.4 NA super corrected
oil objective. The Olympus FV1200 confocal microscope
was equipped with five detectors: two spectral and one filterbased and two gallium arsenide phosphide (GaAsP) photomultiplier tubes (PMTs). The 405-, 488-, and 559-nm diode
lasers and 635-nm HeNe (helium neon) lasers were used
with an optimal pinhole of 1 airy unit to acquire images.
Images were finally processed with ImageJ and Imaris Software (Bitplane, Switzerland).

Transmission electron microscopy and g‑ratio
quantification
Mice were perfused with PBS, brains were removed, and
immersion fixed in 2% PFA, 2.5% Glutaraldehyde, and
0.1 M PBS. 50 μm sagittal brain sections were cut using
a vibratome, then fixed in osmium tetroxide in 0.1 M PBS
(EMS, 19100), followed by dehydration in ethanol and
infiltration of Spurr’s resin. Tissues were embedded using
Spurr’s resin and aclar film. After polymerizing, the corpus
callosum was dissected from the tissue and attached to a premade Spurr’s resin block, then sectioned using a DiATOME
ultra 45° diamond knife and a LEICA Ultracut UC7. 90-nm
sections were cut and picked up onto 200 hex mesh, formvarcarbon coated copper grids (Ted Pella, 01800-F), and stained
with uranyl acetate and lead citrate. Images were captured
using a JEOL 1200 EX II Transmission Electron Microscope
with AMT digital camera. Remyelination was analyzed by
counting the number of naked axons and the number of myelinated axons per field, with a minimum of ten fields being
analyzed. The g-ratio was quantified by dividing the axonal
diameter by the myelinated fiber diameter. Thirty myelinated
axons were randomly analyzed across multiple fields per
mouse to calculate the g-ratio.

In vivo myelin engulfment quantification
Fixed brain slices were permeabilized for 45 min at RT in
PBS 0.1% Triton X-100, followed by 1 h RT in blocking
solution (2% BSA 0.1% Triton X-100 in PBS) and overnight incubation with primary antibody for Rb anti-dMBP
(Millipore, ab5864, 1:2000), Gt anti-Iba1 (Novus, NB1001028, 1:250) and Rt anti-CD68 (Invitrogen, 14-0681-82,
1:300) at 4 °C. Upon washing, sections were incubated 2 h
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at RT with Alexafluor-conjugated secondary antibodies (Invitrogen, 1:1000). Images were acquired with an Olympus
FV1200 laser scanning confocal microscope (OlympusAmerica Inc., Waltham, MA) with 2 × digital zoom, and a
z-step size of 0.33 µm. Z-stacks ranged from 4 to 5 µm in
thickness. Images were processed and analyzed by Imaris
Software (Bitplane, Switzerland). CD68 and Iba1 volume
was quantified by applying 3D surface rendering of confocal
z-stacks in their respective channels, using identical settings
(fix thresholds of intensity and voxel) within each experiment. Each confocal acquisition contained an equal number
of images from the CC of mice treated with AL002a and
control antibody. For quantification of dMBP engulfment
by microglia, only dMBP signals present within microglial
CD68+ structures were considered. To this end, a new channel for ‘‘engulfed dMBP’’ was created, by using the mask
function in Imaris, masking the dMBP signal within CD68+
structures. Quantification of volumes for ‘engulfed dMBP in
CD68’ was performed following the ‘3D Surface rendering
of engulfed material’ protocol previously published [44]. To
account for variations in cell size, the amount of ‘engulfed
dMBP in CD68’ was normalized to the total volume of the
phagocyte in each field (given by Iba1+ total volume). Total
dMBP volume per field from the same confocal z-stacks was
also quantified following the same protocol.

Neurofilament light detection
Mouse blood was collected into EDTA tubes (Sarstedt
201341102) with a capillary tube (Sarstedt 201278100),
spun at 15,000×g for 7 min at 4 °C, and the top plasma
layer was transferred to a 1.5 ml tube and stored at − 80 °C.
Frozen plasma samples were thawed at room temperature,
diluted tenfold, and run on a SIMOA HD-X (Quanterix)
using the Simoa NF-light advantage kit (Quanterix 103186)
according to the manufacturer’s protocol.

BrdU used as a marker of proliferation
Microglia and OPC proliferation in vivo was measured by
5-bromo-2′-deoxyuridine (BrdU) incorporation (Sigma,
B5002). BrdU was administered (25 mg/kg) by intra peritoneal
injection every 12 h starting 4 days before collecting the brains.

Microglia isolation and flow cytometry
Microglia isolation was carried out following a published
protocol [3] with modifications. The whole procedure
was done on ice with cold buffers and centrifuges at 4 °C.
Briefly, anesthetized mice were perfused intracardially with
ice-cold Hank’s balanced salt solution (HBSS), and the CC
and hippocampi were dissected under a stereotactic microscope. The different areas were mechanically homogenized
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and digested in ice-cold Accutase (Millipore) on a wheel
for 20 min at 4 °C. After spinning the tubes for 1 min at
2000g, pellets were resuspended in cold Hibernate buffer
(Thermo Fisher). The cell suspension was then transferred to
pre-chilled 15 ml tubes and passed through a pre-wet (with
Hibernate buffer) 70 µm cell strainer (PluriStrainer Mini).
Cell suspensions were then spun down at 300g for 10 min
and pellets were resuspended in PBS + 2% FBS, counted,
and labeled with a combination of the following conjugated
antibodies: CD11b-PeCy7 (clone M1/70), CD45-Alexa 700
(clone 30-F11), P2ry12-PE (clone S16007D), CD80-FITC
(clone 16-10A1), CD86-BV421 (clone GL-1), and zombie
acqua (Biolegend). Dead cells were excluded by selecting
the zombie aqua negative cells. FACS analysis of the microglial profile was performed by gating C
 D11b+CD45int cells.
Appropriate IgG isotype control antibodies were used for all
staining. FACS analysis was performed on a FACS Fortessa
machine (BD Biosciences), and data were analyzed with
FlowJo Software (TreeStar).

Human tissue and analysis
Twenty fresh-frozen blocks of post-mortem CNS tissue from
eight MS patients and four controls with non-neurological
diseases were obtained from The Neuroinflammatory Disease Tissue Repository at Washington University St. Louis.
Demographic and clinical characteristics of the donors of
human brain tissues at the time of collection are indicated in
Table 1. 5 μm sections were stained with Solochrome Cyanine and Oil Red O to look at myelin and lipid-laden macrophages, respectively. Active lesions were characterized as
tissue areas with marked demyelination and the presence of
lipid-laden macrophages. Tissues were then stained with Gt
anti-human TREM2 (R&D Systems, AF1828, 1:200) and Rb
anti-Iba1 antibody (Wako, 019-19741, 1:600). AlexaFluorconjugated secondary antibodies were used (Invitrogen,
1:1000). Histological images were acquired using the Nanozoomer microscope at the Hope Center for Neurological
Disorders at Washington University. For confocal analysis,
images were acquired with a Zeiss LSM880 Airyscan laser
scanning confocal microscope (Carl Zeiss Inc., Thornwood,
NY) equipped with 63X, 1.4 numerical aperture (NA) Zeiss
Plan Apochromat oil objective. The system is equipped with
a unique scan head, incorporating a high-resolution galvo
scanner along with two PMTs and a 32-element spectral
detector. ZEN 2.3 black edition software was used to obtain
Z-stacks through the entire height of the cells with confocal Z-slices of 5 µm (63 ×) and an interval of 0.347 µm.
Images taken were optimized for 1 airy unit using the 405nm diode, 488 nm Argon, and 561 nm diode and 633 m
HeNe (helium neon) lasers. In addition, the Airyscan unit
provides sub-diffraction limited imaging down to 120 nm
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Table 1  Human CNS tissues from autopsied multiple sclerosis and healthy control subjects
Patient ID

Age/gender

Disease duration at death

Post mortem
interval

Cause of death

MS diagnosis

Tissue

Lesion type

38
10

39/F
41/M

NA
NA

4
24

CNS malignant lymphoma
Heart failure

NA
NA

52
32

69/F
56/F

NA
NA

43
18

Sepsis
Acute myocardial infarction

NA
NA

46
45

77/F
66/F

Unknown
32

16
29

Not reported
Not reported

SPMS
SPMS

77

41/F

15

12

Complication from Type 1
diabetes mellitus

RRMS

40
30
71

60/M
54/F
50/F

14
17
13

9
7
20

Respiratory failure
Pneumonia
Not reported

SPMS
SPMS
SPMS

21

69/F

29

6

Metastatic colon cancer

PPMS

59

54/F

22

8

Pneumonia

SPMS

Cerebellum
Spinal cord
Spinal cord
Cerebrum
Cerebrum
Spinal cord
Cerebrum
Spinal cord
Brainstem
Cerebrum
Brainstem
Spinal cord
Cerebrum
Spinal cord
Spinal cord
Spinal cord
Spinal cord
Spinal cord
Spinal cord
Spinal cord

Control
Control
Control
Control
Control
Control
Control
MS NAWM
MS NAWM
MS NAWM
MS NAWM
MS NAWM
MS NAWM
MS active
MS active
MS active
MS active
MS active
MS active
MS active

NA not applicable, SPMS secondary progressive multiple sclerosis, RRMS relapsing remitting multiple sclerosis, PPMS primary progressive
multiple sclerosis, NAWM normal appearing white matter

resolution. Quantitative PCR analysis was performed on
adjacent tissue sections.

Quantitative PCR
RNA was extracted using the RNeasy Micro Kit (Qiagen),
converted into cDNA using the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems), and used
at 20–40 ng in quantitative real-time PCR (qPCR) analysis. The DDCt method was applied to determine differences in gene expression levels after normalization to the
arithmetic mean of GAPDH as internal standards. The
TaqMan probes used are the following: for human studies:
GAPDH (Hh_99999905_m1) and TREM2 (Hs00219132_
m1); for mouse studies: Gapdh (Mm99999915_g1);
Table 2  Genetic and
demographic characteristics
of Nasu-Hakola and healthy
control subjects included in
gene expression analyses of
monocyte-derived macrophages

Olig2 (Mm01210556_m1); Mbp (Mm01266402_m1);
Cnp (Mm01306641_m1); Mog (Mm00447824_m1); and
Plp (Mm01297210_m1). All data are the mean of duplicates, and the standard errors of the mean was calculated
between duplicates or triplicates. Real-time PCR was performed using an ABI 7000 Real-Time PCR System (Applied
Biosystems).

Human macrophage cultures from Nasu–Hakola
disease (NHD) patients
Peripheral blood mononuclear cells (PBMCs) were purified from peripheral blood samples on Ficoll-Paque PLUS
density gradient (Amersham Biosciences, Piscataway, NJ).
Samples were from three NHD patients and three control

Subject ID

TREM2 genotype

Gender

Age

References

NHD1
NHD2
NHD3
CTR1
CTR2
CTR3

C97T; homozygous
C97T; homozygous
482 + 2T → C; homozygous
Normal TREM2 alleles
Normal TREM2 alleles
Normal TREM2 alleles

F
M
F
F
M
M

46
47
53
60
38
38

[4]
[4]
[39]
[4]
NA
NA

Age was at time of analysis
NHD Nasu–Hakola disease, CTRcontrol/healthy subjects, NA not applicable
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subjects, their characteristics at the time of collection are
indicated in Table 2. To generate macrophages, PBMCs
were seeded in RPMI without FBS for 2 h, then PBMCs
were thoroughly washed with PBS, and cultured in complete
media (RPMI, 10% FBS, Pen/Strep, l-glutamine, non-essential amino acid) supplemented with (50 ng/ml) of recombinant human M-CSF (300-25, Peprotech) for 7 days at 37 °C
in 5% C
 O2. Cells were then harvested and immediately lysed
in RLT Buffer; RNA was extracted using the RNeasy Micro
Kit (Qiagen).

Microarray processing and analysis
In order to analyze the Affymetrix HuGene-1_0-st-v1
microarrays, CEL files were uploaded into Thermo Fisher’s Transcriptome Analysis Console (TAC) Software. We
normalized the data in TAC and did differential expression
analysis to compare gene expression in 3 control samples
with 3 samples carrying TREM2 homozygous mutations.
The differentially expressed genes were graphed in a volcano plot, with the − log10 of the P value on the Y-axis and
the fold change on the X-axis. A twofold or greater change
in gene expression and a P value of 0.05 were considered
significant and colored red for up-regulated genes and green
for down-regulated genes.

Data are displayed as individual dots and mean ± SEM. For
each graph, the number of observations indicated with ‘‘n’’
and the number of biological replicates (mice) indicated
with ‘‘N’’ can be found in the figure legends. Differences
between multiple groups were analyzed by one-way ANOVA
and a post hoc test (Tukey’s or Sidak’s or Dunnett’s). Comparisons between two groups following a normal distribution
were analyzed using an unpaired t test (two-tail distribution)
or a Mann–Whitney test when the distribution was not parametric, as indicated in each figure. Statistical analysis was
performed using GraphPad Prism (Graph-Pad Software).
Values were considered significant if P < 0.05.

Results
TREM2 is highly expressed in active MS lesions
The general consensus is that TREM2 is expressed by
microglia in the CNS, especially after activation [6, 21, 47].
TREM2 expression was reported in active demyelinating
lesions on myelin-laden macrophages (called foamy macrophages), which are clearing out myelin debris, a critical
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Fig. 1  TREM2 is highly expressed in active MS lesions. a Top to bottom: white matter with no pathology in control non-MS individuals
(CONTROL), normal appearing white matter of MS subjects (MS
NAWM) and MS active lesions in the white matter (MS ACTIVE)
are stained with solochrome cyanine staining (SOLOCY) and with
Oil Red O staining (ORO). Original magnification SOLOCY: × 10;
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step to allow remyelination [41]. Yet, a systematic characterization of TREM2 expression on microglia-macrophages
in different types of MS lesions has not been done. Here
we studied TREM2 expression by immunohistochemistry
(IHC) and real-time qPCR in human CNS tissues derived
from autopsy of subjects with MS or unaffected controls
(Table 1). We specifically analyzed MS active lesions and
normal appearing white matter (NAWM) in MS subjects
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and white matter with no pathology in non-MS individuals
as control. By confocal analysis we showed TREM2 specific expression in ionized calcium-binding adapter molecule
1(Iba1)+ cells in active MS lesion, which were identified as
oil-red O+ lipid laden macrophages-microglia by histology
(Fig. 1a, b). TREM2 was not detectable by IHC on Iba1+
microglia in NAWM in MS subjects as well as in the white
matter of control individuals (Fig. 1b).
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◂Fig. 2  In vitro and in vivo effects of a TREM2-specific antibody on

TREM2 signaling. a WB analysis of Trem2+/+ or Trem2−/− BMDM
stimulated with a TREM2-specific antibody (AL002a) or with a control antibody, by cross-linking with a secondary antibody (x-link) or
in solution (soluble; for Trem2+/+ only). Cells were immunoprecipitated with a rat anti-h/m-TREM2 antibody and fractionated by SDSPAGE in non-reducing conditions. Phopho DAP12 (pTyr) is shown
here as a dimer. b Quantification of DAP12-pTyr normalized on actin
is shown as fold change over control. ***P < 0.001, ****P < 0.0001,
One-way ANOVA with Tukey’s post hoc test. c Peritoneal cells
isolated from Trem2+/+ mice after thyoglicollate treatment, immunoprecipitated with an anti-TREM2 antibody (clone 237920), and
analyzed by WB. d Quantification of DAP12- pTyr normalized on
actin. ****P < 0.0001, two-tailed unpaired Student’s t test. e Activation of TREM2 signaling in the BWZ reporter cell assay with different concentrations of plate-bound myelin. BWZ cells express either
NFAT:luciferase alone (BWZ control) or in combination with mouse
TREM2 and DAP12 (BWZ TREM2). ****P < 0.0001, Two-way
ANOVA with Sidak’s post hoc test. f TREM2 signaling in the BWZ
Trem2 reporter cell assay at different concentrations of AL002a antibody. ***P < 0.001, ****P < 0.0001, Two-way ANOVA with Dunnett’s post hoc test. g Myelin-induced signaling by AL002a (10 µg/
ml) in the BWZ Trem2 reporter cell assay at different concentrations
of plate-bound myelin. *P < 0.05, Two-way ANOVA with Dunnett’s
post hoc test. CTRcontrol

To quantify TREM2 expression in different lesion types,
we performed quantitative real-time RT-PCR (RT-qPCR)
studies which demonstrated that TREM2 expression is significantly higher in active MS lesions compared to MS NAWM
or white matter from controls (Fig. 1c).
These results provide evidence that TREM2 is highly
expressed by I ba1+ cells present in active demyelinating MS
lesions. Therefore, we sought to further evaluate TREM2
potential involvement in the context of CNS demyelination
and myelin debris clearance by microglia.

Effects of a newly generated TREM2‑specific
antibody on TREM2 signaling
To characterize TREM2 functions on microglia during CNS
demyelination, we generated a monoclonal antibody targeting mouse TREM2, called AL002a. The antibody’s specificity was verified by binding to wild-type (Trem2+/+), but
not Trem2−/− thioglycollate-induced macrophages (THGMac) (Supplementary Fig. 1a). To test whether AL002a
induced signaling after receptor engagement, Trem2+/+ and
Trem2−/− BMDM were stimulated in vitro with AL002a, followed by crosslinking with a secondary antibody to induce
receptor clustering. AL002a induced phosphorylation of the
TREM2-associated adaptor protein DAP12 in Trem2+/+, but
not in Trem2−/− BMDM (Fig. 2a, b; DAP12 phosphorylation is indicated as DAP12-pTyr). Treatment with an isotype control antibody did not show any DAP12 activation.
DAP12 phosphorylation was also induced when BMDM
were stimulated with AL002a without secondary crosslinking (soluble) (Fig. 2a, b). These results demonstrate
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that AL002a is a strong inducer of DAP12 phosphorylation
(after cross-linking and as soluble), and it acts as an agonist
of TREM2 signaling.
Next, we investigated whether AL002a was able to
induce TREM2 clustering and signaling activation in vivo.
Mice were injected with the anti-TREM2 antibody after
thioglycollate-induced recruitment of macrophages to the
peritoneal cavity. AL002a induced phosphorylation of
DAP12-associated TREM2 compared to the isotype control (Fig. 2c, d). These results demonstrate that AL002a is
a potent inducer of TREM2 intracellular signaling in vitro
(by both cross-linking and soluble stimulation) and in vivo
(by soluble stimulation).
It was previously demonstrated that TREM2 recognizes myelin-associated lipids [42, 52], suggesting that
TREM2 may directly sense lipid components exposed after
myelin damage. To confirm these results, we developed a
cell reporter assay, using BWZ cells expressing the mouse
TREM2/DAP12 complex and transduced with a luciferase
reporter gene under NFAT promoter control. TREM2 clustering promotes calcium flux stimulating NFAT-activity
that induces luciferase expression [50]. In the presence of
purified human myelin, TREM2 signaling was activated in
the BWZ cell reporter system in a dose-dependent fashion
(Fig. 2e). Next, we tested the ability of soluble AL002a to
activate TREM2 signaling in the reporter cell assay. AL002a
induced TREM2 signaling as demonstrated by incremental
luciferase induction in a dose-dependent manner (Fig. 2f).
Subsequently, we tested whether TREM2 antibodies could
block or enhance myelin-induced TREM2 signaling. To this
end, we added AL002a to BWZ cells seeded on increasing concentrations of plate-bound myelin. At lower myelin
concentrations (< 100 µg/ml), AL002a antibody did not
modulate signaling; in contrast, at higher concentrations
(> 100 µg/ml), AL002a significantly increased myelininduced luciferase activation (Fig. 2g). These results show
that AL002a potentiates myelin-mediated TREM2 signaling
activation in vitro.
In conclusion, our data demonstrate that AL002a acts as
a potent TREM2 agonist both in vitro and in vivo, and its
agonistic activity is boosted by the presence of myelin.

Trem2 haploinsufficiency results in defective
myelin debris clearance in the CPZ model of CNS
demyelination
We and others have previously shown that Trem2−/− mice
present a significant defect in clearance of myelin debris
in the CPZ-induced model of demyelination compared to
Trem2+/+ mice [8, 42]. Whether heterozygous (Trem2+/−)
mice would present the same or a milder phenotype than
Trem2−/− mice has not been evaluated before in the CPZ
model. Here, Trem2 +/+, Trem2 +/−, and Trem2 −/− mice
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Fig. 3  Trem2+/- mice show defective myelin debris clearence after
CPZ-induced demyelination. a Representative images of the corpus
callosum (CC) of Trem2+/+, Trem2+/− and Trem2−/− mice fed with
cuprizone (CPZ) for 4 weeks and then analyzed. Myelin was studied histologically by solochrome cyanine (SOLOCY) staining (intact
myelin is stained in dark blue). Scale bar, 300 µm. dMBP (green)
was used to assess myelin debris; microglia were analyzed as density of 
Iba1+ cells (red); DAPI (blue). Original magnification, ×
10. Scale bar, 200 µm. Quantification of b dMBP fluorescent staining and c microglia density in the CC after 4 weeks on CPZ. dMBP
quantification: Trem2+/+ N = 8 mice, n = 16 fields; Trem2+/− N = 6,
n = 12; Trem2−/− N = 8, n = 16. Iba1 quantification: Trem2+/+ N = 5,

n = 10; Trem2+/− N = 4, n = 8; Trem2−/− N = 5, n = 10. ***P < 0.001,
****P < 0.0001, One-way ANOVA with Tukey’s post hoc test. Representative images of PDGFRα (red) (d) and GFAP (red) (f) in the
CC of Trem2+/+, Trem2+/− and Trem2−/− mice after 4 weeks on CPZ.
Original magnification, × 10. Scale bar, 200 µm. Quantification of e
PDGFRα and g GFAP fluorescent staining in the CC after 4 weeks
on CPZ. PDGFRα quantification: Trem2+/+ N = 6, n = 12; Trem2+/−
N = 6, n = 12; Trem2−/− N = 8, n = 16. GFAP quantification: Trem2+/+
N = 9, n = 18; Trem2+/− N = 6, n = 12; Trem2−/− N = 8, n = 16.
*P < 0.05, ****P < 0.0001, One-way ANOVA with Tukey’s post hoc
test

were fed with CPZ for 4 weeks to induce CNS demyelination and to evaluate microglia response to the injury,
the degree of myelin debris clearance and remyelination.
We performed IHC analyses within the corpus callosum
(CC) (Supplementary Fig. 1b), a site of particularly profound and consistent demyelination in the CPZ model [31].
Solochrome cyanine staining was performed to qualitatively visualize myelin in the CC (Fig. 3a). Intact myelin
was colored in dark blue in naïve mice (Supplementary
Fig. 1c). In contrast, a light blue myelin staining was evident in the CC in Trem2+/−, and Trem2−/− mice fed CPZ.
This was suggestive of tissue accumulation of myelin
debris, as we have observed in our previous study [8].
To assess the amount of myelin debris accumulation in

the tissue we detected degraded myelin basic protein
(dMBP) by using an antibody able to bind MBP epitopes
exposed only after myelin degradation [30]. As previously
reported, when compared to Trem2 +/+, Trem2 −/− mice
after 4 weeks on CPZ displayed a significant increase
in dMBP signal, accompanied by a significant reduction
in Iba1+ microglia [8] (Fig. 3a–c) and in OPC numbers,
identified as Platelet-Derived Growth Factor Receptor
Alpha (PDGFRα)+ cells (Fig. 3d, e). No differences were
found in astrocyte activation, quantified as glial fibrillary
acidic protein (GFAP) positive cells (Fig. 3f, g). Notably,
Trem2 +/− mice displayed a phenotype which was intermediate between Trem2+/+ and Trem2−/− mice showing a
significant increase in dMBP (Fig. 3a, b) and significantly
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Fig. 4  Treatment with the AL002a antibody during CPZ-induced
CNS demyelination in Trem2+/− mice promotes myelin debris clearance in the corpus callosum. a Timeline of antibody treatment during
cuprizone experiment. Weeks on CPZ = WKS ON (green numbers);
days after CPZ withdrawal = OFF (red numbers). Mice were sacrificed after 4 weeks on CPZ (WK 4), 4 weeks on CPZ followed by
3 days (+ 3D), 7 days (+ 7D) or 14 days (+ 14D) of recovery (red
asterisks correspond to the time points in which the tissues were collected). b Representative images of solochrome cyanine (SOLOCY)
staining and of dMBP (green) and DAPI (blue) immunostaining in
the CC of Trem2+/− mice at the different time points. Original magnification, × 10. Scale bar, SOLOCY, 300 µm; dMBP, 200 µm. c Quan-

tification of dMBP debris at the different time points. CTR group:
WK 4 N = 5 mice, n = 10 fields; WK 4 + 3D N = 6, n = 12; WK 4 + 7D
N = 5, n = 10; WK 4 + 14D N = 5, n = 5; AL002a-treated group:
WK 4 N = 5, n = 10; WK 4 + 3D N = 5, n = 10; WK 4 + 7D N = 4,
n = 8; WK 4 + 14D N = 6, n = 6. ****P < 0.0001, two-tailed unpaired
Student’s t test. d 3D reconstruction by Imaris of Iba1+ cells (red) and
dMBP (green) immunostaining in the CC at WK 4 + 3D. Original
magnification, × 63. Scale bar, 10 µm. e Quantification of dMBP total
volume per field in mice treated with AL002a or CTR. CTR group:
N = 6, n = 12; AL002a treated group: N = 6, n = 11. **P < 0.01, twotailed unpaired Student’s t test

less PDGFRα+ OPCs compared to Trem2+/+ mice (Fig. 3d,
e). No differences were noted in the number of Iba1+ nor
GFAP+ cells in the CC in Trem2+/− compared to Trem2+/+
mice (Fig. 3a, c, f, g), in contrast to the significant reduction of the microglia number observed in Trem2 −/− vs.
Trem2+/+. These results suggest that the presence of a fully
functional TREM2 receptor on microglia is critical for
efficient myelin debris removal and quick OPC recruitment observed in Trem2+/+ mice. Trem2 haploinsufficiency
leads to inefficient myelin debris clearance, reduced OPC
recruitment, even if it does not impact on the number of
microglia accumulating in the CC.

Treatment of Trem2+/− mice with AL002a antibody
accelerates myelin debris clearance
Next, we assessed the potential impact of AL002a on myelin debris clearance during CPZ-induced demyelination in
Trem2+/− mice. To this end, Trem2+/− mice were treated with
AL002a or an isotype control given intraperitoneally 4 days
before starting CPZ feeding and then weekly throughout the
experiment (Fig. 4a). AL002a was able to reach the brain and
it was detected in the CC and in the cortex (Ctx) (Supplementary Fig. 1d). Analyses were performed at 4 weeks (WK
4; when the peak of demyelination is observed) after CPZ
feeding and then at 3 days (WK 4 + 3D), 7 days (WK 4 + 7D),
and 14 days (WK 4 + 14D) after CPZ withdrawal, when mice
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were fed regular chow to allow remyelination. Treatment
in vivo with AL002a resulted in the amelioration of CPZinduced pathology in Trem2+/− mice. Specifically, AL002a
treatment enhanced myelin debris clearance compared to
Trem2+/− mice treated with the control antibody, as demonstrated by a significant reduction in dMBP staining at WK
4 + 3D after CPZ withdrawal (Fig. 4b, c). This finding was
also confirmed by confocal microscopy and 3D-reconstruction, which showed a significant reduction of dMBP amount
(quantified as dMBP volume) per field at the same timepoint
in AL002a versus control-treated Trem2+/− mice (Fig. 4d, e).
Since TREM2 receptor is specifically expressed by microglia in the brain, these results strongly suggest that AL002a
antibody accelerates myelin clearance in the CPZ model of
demyelination by potentiating TREM2 receptor function on
microglial cells.

AL002a antibody promotes myelin uptake
and degradation in vivo and in vitro
Microglia play a key role in myelin debris removal after
CNS demyelination [33]. Microglia internalize and phagocytose myelin which is then degraded intracellularly by lysosomal structures. We hypothesized that reduction in dMBP
staining observed after AL002a treatment could be related
to an increased ability to uptake and/or to degrade myelin
fragments by Trem2+/− microglia. To clarify these aspects,
the amount of dMBP within microglial phagolysosomes
was analyzed by immunofluorescence in the CC at WK
4 and WK 4 + 3D. Quantitative confocal analysis and 3D
reconstruction of I ba1+ cells showed a significant increase
in dMBP amount inside C
 D68+ phagolysosomal structures
at WK 4 in AL002a vs. control treated mice (Fig. 5a, c).
Interestingly, 3 days after toxin withdrawal we observed
that dMBP in phagolysosomes was lower in AL002a-treated
mice compared to control (Fig. 5b, c; P = 0.07). These findings suggest that AL002a antibody treatment enhanced
myelin debris internalization by microglia at WK 4, as
demonstrated by a higher dMBP amount detected inside
CD68+ structures in microglia (Fig. 5a, c), accompanied by
decreased dMBP total volume per field (Fig. 4b, c) at WK
4 + 3D. Moreover, the reduction in dMBP content within
lysosomal structures after 3 days from toxin withdrawal
implies that AL002a further accelerated intracellular myelin
processing and degradation.
To confirm that AL002a antibody was improving myelin
uptake and degradation capacity by microglia, we performed
an in vitro myelin phagocytic and degradation assay. To
assess myelin phagocytosis, BMDMs from Trem2+/− mice
were pre-treated with AL002a or control antibody and then
myelin was added to the culture. Analysis of MBP internalization by immunofluorescence revealed a significant
increase in MBP amount detected inside Iba1+ cells treated
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with AL002a after 1 h (Fig. 5d, e), while no differences
between the two groups were detected at 30’ and 3 h. This
suggests a time-dependent increase in myelin uptake by
BMDM after AL002a treatment and further supports our
in vivo findings showing higher dMBP amount inside microglia at WK 4 on CPZ in AL002 treated group (Fig. 5a, c).
To assess the effect of AL002a on myelin degradation,
Trem2+/− BMDM were pre-treated with AL002 or control
antibodies, then incubated with human myelin for 2 h, and
subsequently washed in order to remove extracellular myelin
not taken up. MBP content by BMDM was then quantified
after 1, 24, and 48 h. We observed a significant reduction in
myelin content in BMDM treated with AL002a compared
to those treated with the control antibody both at 24 and
48 h (Fig. 5f, g). Therefore, AL002a leads to a significant
increase in myelin phagocytosis by Trem2+/− BMDM after
1 h, and also it accelerates their degradative capacity at later
time points. These findings are consistent with the observation that AL002a treatment promotes a more efficient clearance of myelin debris by Trem2+/− microglia in vivo in the
CPZ model.

Treatment with AL002a enhances the activation
state of Trem2+/− microglia
AL002a could potentially promote myelin debris clearance
by Trem2+/− microglia after CPZ by increasing microglia
numbers in the areas of demyelination and/or their phagocytic functions. Since we did not observe any difference in
microglia density (Supplementary Fig. 2a and b) nor proliferation (the latter quantified as Iba1+BrdU+ cells at WK
4 + 3D; Supplementary Fig. 2c and d) in Trem2+/− mice after
treatment with AL002a, we hypothesized that AL002a antibody could enhance microglia activation state as well as
phagocytic and lysosomal activity.
FACS analysis of CD11b+ CD45int microglia isolated
from the CC (Fig. 6a and Supplementary Fig. 3a) showed a
significant increase in CD80 costimulatory molecule at WK
4 measured both as mean fluorescence intensity (MFI) and as
cell percentage in AL002a treated vs. control (Fig. 6b, c). No
differences were observed in CD86 and CD11b expression
on microglia (Fig. 6b, c). Iba1 intensity in the CC, detected
by immunofluorescence, was also higher in AL002a-treated
compared to the control group at WK 4 (Fig. 6f, g), thus confirming the increased activation of microglia after AL002a
treatment. At 3 days after CPZ withdrawal, there were no
differences in microglia activation state between the two
groups (Fig. 6c–e), thus indicating that CPZ removal was
sufficient to revert AL002a effects on microglia inflammatory state. A strong upregulation of activation markers after
AL002a treatment was also detectable in microglia isolated from the hippocampus (HP) at WK 4 (Supplementary
Fig. 3b–g), an area which is also affected by pathology after
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Fig. 5  AL002a treatment enhances myelin uptake and processing
by Trem2+/− microglia in vivo and by BMDM in vitro. Representative confocal z-stack and relative 3D surface rendering showing
volume reconstruction of microglia (red), CD68 (gray) and dMBP
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AL002a and control antibodies (10 µg/ml) and treated with myelin
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48hr
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for 0.5, 1 and 3 h. Iba1 (red), MBP (green), DAPI (blue). Original
magnification, × 10. Scale bar, 100 µm. CTR group: 30’ n = 80;
1 h n = 100; 3 h n = 80; AL002a group: 30’ n = 80; 1 h n = 100; 3 h
n = 80. **P < 0.01, two-tailed unpaired Student’s t test. f Representative images and g relative quantification of Trem2+/− BMDM assayed
for their degradative capacity. Trem2+/− BMDM were pre-stimulated
with AL002a or control antibodies (10 µg/ml), then incubated with
human myelin for 2 h and washed. MBP content in Iba1+ cells was
quantified after 1, 24, and 48 h. CTR group: 1 h n = 42; 24 h n = 104;
48 h n = 80; AL002a group: 1 h n = 48; 24 h n = 110; 48 h n = 80.
**P < 0.01, two-tailed unpaired Student’s t test. d–g Three independent experiments were performed
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CPZ administration [15]. This result further corroborates
AL002a effect in promoting microglia activation in the CPZ
model of demyelination.
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Additionally, at WK 4 after CPZ, the lysosomal-associated membrane protein 1 (LAMP1), a protein essential
for the fusion of phagosomes with lysosomes and their
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◂Fig. 6  Increased Trem2+/− microglia activation following AL002a

antibody treatment in vivo. a FACS analysis of Trem2+/− microglia isolated from the CC at WK 4. Microglia were identified as
CD11b+CD45int cells upon doublet discrimination and death cell
exclusion. Values indicated in FACS plots represent the relative frequency of live cells after duplets exclusion. b Histograms showing
the mean fluorescence intensities (MFIs) of surface CD80, CD86,
and CD11b at WK 4 and c their relative quantification at WK 4 and
WK 4 + 3D. d Example plots of flow cytometric analysis of CD80
positive microglia at WK 4 and e quantification of the microglia percentage expressing CD80 molecule at WK 4 and WK 4 + 3D. CTR
group N = 5 and AL002a treated group N = 4; *P < 0.05, two-tailed
unpaired Student’s t test. f Representative confocal images of Iba1
(red) and DAPI (blue) in the CC at WK 4. Original magnification,
× 63. Scale bar, 10 µm. g Quantification of Iba1 intensity (measured
as area) at WK 4 and WK 4 + 3D. CTR group: WK 4 N = 5 mice,
n = 15 fields; WK 4 + 3D N = 6, n = 16; AL002a-treated group: WK
4 N = 5, n = 15; WK 4 + 3D N = 6, n = 11; **P < 0.01 two-tailed
unpaired Student’s t test. h Representative images of LAMP1 (red),
Iba1(green) and DAPI (blue) at WK 4. Original magnification, × 20.
Scale bar, 400 µm. i Quantification of LAMP1+ signal colocalizing
with Iba1+ cells. CTR group: WK 4 N = 5, n = 20; WK 4 + 3D N = 6,
n = 23; AL002a treated group: WK 4 N = 5, n = 20; WK 4 + 3D N = 5,
n = 18; *P < 0.05, two-tailed unpaired Student’s t test. j Representative images of CD68 (red), Iba1 (green) and DAPI (blue) at WK 4.
Original magnification, × 20. Scale bar, 400 µm. k Quantification of
CD68+ signal colocalizing with Iba1+ cells. CTR group: WK 4 N = 5,
n = 10; WK 4 + 3D N = 6, n = 24; AL002a-treated group: WK 4 N = 5,
n = 10; WK 4 + 3D N = 5, n = 20; **P < 0.01 two-tailed unpaired Student’s t test

subsequent degradation [12], was significantly increased in
microglia from AL002a-treated mice compared to controls
(Fig. 6h, i). WK 4 represents the peak of demyelination
and microglia are actively phagocytosing myelin debris at
this time. Notably, we also detected a significant increase
in CD68+ phagosome structures in Trem2+/− microglia at
WK 4 + 3D compared to control (Fig. 6j, k). This further
supports enhanced in vivo phagocytic activities by microglia
following AL002a-induced activation.

AL002a treatment leads to increased OPC density,
OL maturation, and remyelination
Microglia activation and myelin debris clearance are critical steps for successful remyelination [29]. Therefore,
we hypothesized that AL002a treatment, by promoting
myelin debris clearance by microglia, could positively
impact remyelination. We have previously shown that
increased accumulation of damaged myelin in the CC of
Trem2+/− mice, compared to Trem2+/+ mice, was associated
with a reduced number of PDGFRα+ OPCs (Fig. 3a, b, d,
e). Efficient clearance of myelin debris after demyelination
can favorably impact OPC recruitment and differentiation
into remyelinating oligodendrocytes [29]. We observed a
significant increase in PDGFRα+ OPC density in the CC
of Trem2+/− mice after AL002a antibody treatment at WK
4 + 3D and WK 4 + 7D compared to control (Fig. 7a, b).
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No differences in PDGFRα+ OPC proliferation, quantified as density of PDGFRα+BrdU+ cells, were observed at
WK 4 + 3D (Supplementary Fig. 4a, b). These results suggest that AL002a antibody could promote the recruitment of
OPCs from surrounding brain regions, rather than enhancing
the proliferation of resident OPCs in the CC. We then analyzed the expression of OLIG2 and CNPase, markers specifically expressed by mature OL. We observed a significant
increase of both O
 LIG2+ and C
 NPase+ cells upon AL002a
treatment vs. control at WK 4 + 3D after CPZ withdrawal
(Fig. 7c–e). The same increase in Olig2 and Cnp genes was
detected by RT-qPCR analyses at WK 4 +7D in both the
CC and HP (Supplementary Fig. 4c and d). In parallel, we
observed a significant increase in the mRNA of myelin genes
such as myelin basic protein (Mbp), myelin-associated protein (Mag), and proteolipid protein 1 (Plp1) in both regions
(Fig. 7f–h). Finally, to assess remyelination and thickness of
the new myelin sheaths in the CC, we performed transmission electron microscopy (TEM) analysis on sagittal sections of Trem2+/− mice naïve or fed with CPZ and analyzed
after withdrawal at WK 4 + 3D and WK 4 + 7D (Fig. 7i).
Specifically, myelinated axons (MA) and naked axons were
counted in the CC of naïve mice (MA: 89% ± 0.00724 as
mean ± SEM) or in mice fed with CPZ and treated with
AL002a or control antibody. Significantly more MA were
counted in the CC after AL002a treatment compared to control at WK 4 + 3D (MA: 32% ± 0.0192 in AL002a-treated
group vs. MA: 23% ± 0.0122 in control group) and this was
even more pronounced at WK 4 + 7D (MA: 53% ± 0.0124
in AL002a-treated group vs. MA:42% ± 0.0179 in control
group) (Fig. 7j). In addition, g-ratio analysis revealed significantly increased myelin sheath thickness in mice treated with
AL002a at WK 4 + 3D and WK 4 + 7D compared to control
(Fig. 7k). All together, these data strongly suggest that activation of TREM2, through AL002a antibody, increased OPC
accumulation within the CC lesioned area, enhanced OPC
differentiation into mature oligodendrocyte, and accelerated
remyelination.

AL002a treatment preserves axonal integrity
Remyelination is known to protect axons from ongoing degeneration [18]. Therefore, we further investigated
whether AL002a together with promoting remyelination was
also positively impacting axonal health. We assessed levels
of neurofilament-light chain (Nf-L), which are released in
significant quantity following axonal damage or neuronal
degeneration, in Trem2+/− mice treated with AL002a or
control antibody. Mice treated with AL002a showed significantly lower Nf-L levels in the plasma at WK 4 + 3D
compared to the control, with a trend of reduced levels also
observed at WK 4 + 7D (Fig. 8a). These results are suggesting that AL002a treatment during CPZ-induced CNS
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demyelination will also preserve axonal integrity. Further
evidence supporting a neuroprotective effect exerted by
AL002a, came from the evaluation with the SMI-31 antibody (a marker of healthy axons) in the CC, which was significantly increased in AL002a compared to control treated
Trem2+/− mice at WK 4 + 7D (Fig. 8b, c). In conclusion,
AL002a treatment preserved axonal health during CPZ treatment, thus preventing neurodegeneration.
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Macrophages derived from Nasu–Hakola subjects
display a defect in phagocytic pathways
TREM2 function in human microglia is still elusive and this
is also due to experimental difficulties and limitations of
human studies. A role of TREM2 in phagocytic pathways
in the human brain was previously suggested [13]. Here, we
have analyzed the gene expression profile of macrophages
obtained from the peripheral blood of three patients affected
by NHD (lacking TREM2 receptor), compared to healthy
control individuals. NHD is characterized by loss of myelin

Acta Neuropathologica (2020) 140:513–534
◂Fig. 7  AL002a -treated mice show increased OPC density, mature

myelin and remyelination after CPZ-induced demyelination. a Representative images of PDGFRα+ (red) and DAPI (blue) in the CC at
WK 4 + 3D and WK 4 + 7D. Original magnification, × 20. Scale bar,
400 µm. Insert magnification, × 60. Scale bar, 25 µm. b Quantification of PDGFRα+ cell density. CTR group: WK 4 + 3D N = 6 mice,
n = 24 fields; WK 4 + 7D N = 5, n = 20; AL002a-treated group:
WK 4 + 3D N = 6, n = 24; WK 4 + 7D N = 5, n = 20; **P ≤ 0.01;
****P ≤ 0.0001; WK 4 + 3D two-tailed Mann–Whitney test;
WK 4 + 7D two-tailed unpaired Student’s t test. c Representative
images of OLIG2 (green), CNPase (red) and DAPI (blue) in the CC
at WK 4 + 3Ds and WK 4 + 7D. Original magnification, × 10. Scale
bar, 200 µm. Insert magnification, × 60. Scale bar, 25 µm. d Quantification of the density of O
 LIG2+ cells at both the time points. e
Quantification of the percentage of C
 NPase+ staining in the CC.
CTR group: WK 4 + 3D N = 6, n = 12; WK 4 + 7D N = 5, n = 10;
AL002a-treated group: WK 4 + 3D N = 5, n = 10; WK 4 + 7D N = 4,
n = 8; *P < 0.05, **P ≤ 0.01; two-tailed unpaired Student’s t test. RTqPCR quantification of mRNA levels of myelin basic protein (Mbp)
(f), myelin oligodendrocyte glycoprotein (Mog) (g) and proteolipid
protein 1 (Plp1) (h) in the corpus callosum (CC) and the hippocampus (HP) of Trem2+/− mice treated with AL002a antibody or CTR.
Tissues were collected at WK 4 + 7D. CTR group: N = 5, AL002atreated group: N = 5 (Mpb); N = 4 (Mog); N = 3 (Plp1). *P < 0.05,
two-tailed unpaired Student’s t test. i Electron microscopy (EM)
of a naïve mouse and mice treated with AL002a or isotype control
antibody at WK 4 + 3D and WK 4 + 7D. Green plus sign indicates
myelinated axons and red minus sign indicates naked axons. Original image = × 5000. Scale bar = 2 µm. j Percentage of myelinated
axons (MA) and naked axons (NA) in naïve mice, and in CTR and
AL200a-treated mice at WK 4 +3D and WK 4 + 7D. ***P < 0.001
at WK 4 + 3D and ****P < 0.0001 at WK 4 + 7D, two-tailed Mann–
Whitney test. k G-ratio of myelinated fibers in naïve mice, and in
CTR and AL002a-treated mice at WK 4 + 3D and WK 4 + 7D. Each
dot represents one axon. Naïve mice N = 2, CTR treated mice at WK
4 + 3D N = 5 and at WK 4 + 7D N = 5; AL002a-treated mice at WK
4 + 3D N = 4 and at WK 4 + 7D N = 5. ***P < 0.001 at WK 4 + 3D
and ****P < 0.0001 at WK 4 + 7D, two-tailed unpaired Student’s t
test

and microglia activation in the CNS [25]. These studies
aimed to investigate whether a TREM2 loss of function
mutation in NHD patients could result in the dysregulation
of gene expression pathways involved in the clearance of
myelin debris in the brain.
The cohort of subjects that we studied was composed
of: (1) two siblings affected by NHD and carrying an
homozygous loss-of-function point mutation in exon 2 of
the TREM2 gene (C97T) causing a glutamine in position
33 to be changed in a stop codon (Q33X) [4]; (2) one unaffected sibling from the same family, homozygous for the
normal TREM2 allele, who was included as a control; (3)
one NHD subject carrying a different homozygous mutation
in the splice-donor consensus site of intron 3 of TREM2
(482 + 2T → C) [9]; (4) two unrelated healthy control subjects. Genetic and demographic characteristics are summarized in Table 2. Macrophages from each subject were
differentiated in vitro from peripheral blood monocytes,
and gene expression analysis was performed by microarray
analysis. A total of 20,874 genes were tested to compare
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their expression between NHD subjects (n = 3) and unaffected controls (n = 3). 2526 genes were found to be differentially expressed with absolute fold change > 2 (ANOVA
P value < 0.05). The heat map for these genes is displayed
in Fig. 9a. Only 11 genes, including TREM2, remained significant after adjustment of the absolute fold change cutoff to
a FDR < 0.05 [40] (Supplementary Table 1). Principal component analysis showed the ability of gene expression data
to discriminate NHD from control subjects (Supplementary
Fig. 4e). Gene ontology (GO) analysis revealed that genes
involved in the phagosome pathway are among the toppathways significantly altered in NHD subjects compared to
controls along with changes in immune response pathways
(Fig. 9b, and Supplementary Table 2 and 3). Interestingly,
differentially expressed genes in the phagosome pathway
were all downregulated in NHD vs. unaffected control subjects. The distribution of their fold changes and P values is
represented in a volcano plot in Fig. 9c. Furthermore, we
performed a co-expression analysis for TREM2 using public RNA-seq data from 31,499 samples and then compared
these genes with the differentially expressed genes in NHD
patients (Supplementary Table 4). A GO cellular component
analysis confirmed that genes from the phagocytic pathway
are both significantly co-expressed with TREM2 and altered
in NHD patients (Supplementary Table 5). Overall, these
data from NHD individuals, confirmed that TREM2 receptor
plays a critical role in phagocytic pathways in human myeloid cells and that during NHD pathology genes involved in
phagocytosis are specifically dysregulated.

Discussion
This study provides evidence of beneficial effects of treatment with the new agonistic anti-TREM2 antibody AL002a
in the CPZ model of CNS demyelination. We showed that
TREM2 is highly expressed on microglia/macrophages
phagocyting myelin in MS active lesions. In CPZ-induced
demyelination we further validated previous findings that
loss of TREM2 reduces myelin clearance and we showed
that loss of one copy of TREM2 has an intermediate phenotype, suggesting that myelin removal by microglia is sensitive to TREM2 copy numbers. We then demonstrated that
treatment with AL002a in vivo promotes efficient clearance
of myelin debris, with increased myelin phagocytosis and
intracellular degradation after CPZ-induce demyelination.
This was accompanied by increased microglia activation and
by a higher expression of proteins involved in phagocytic and
degradative pathways. Most importantly, AL002a treatment
increased OPC density and differentiation into mature OL to
support remyelination, thus finally leading to axonal health
preservation. Notably, macrophages from NHD individuals with loss-of-function homozygous TREM2 mutations
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Fig. 8  AL002a positively impacts axonal health after CPZ-induced
demyelination. a Neurofilament light chain (Nf-L) levels were measured in plasma samples collected from Trem2+/− naïve mice and
Trem2+/− mice treated with AL002a antibody or CTR at WK 4 +3D
and WK 4 + 7D after CPZ-induced CNS demyelination. Naïve mice,
N = 9; CTR group: WK 4 + 3D N = 10; WK 4 + 7D N = 10; AL002atreated group: WK 4 + 3D N = 10; WK 4 + 7D N = 8. *P < 0.05,

**P ≤ 0.01; one-way ANOVA with Tukey’s post hoc test. b Representative images and c quantification of SMI31 (red) fluorescent
staining at WK 4 + 3D and WK 4 + 7D in the CC. CTR group: WK
4 + 3D N = 6 mice, n = 12 fields; 4 + 7D N = 5, n = 10; AL002a-treated
group: WK 4 + 3D N = 6, n = 12; WK 4 + 7D N = 5, n = 10 fields;
*P < 0.05; two-tailed unpaired Student’s t test

showed a defect in the phagocytic pathways, suggesting that
findings from mouse studies may translate to humans.
Growing evidences suggest the important role of
TREM2 in microglia function. We previously showed that
Trem2−/− mice have a striking defect in microglia activation
and myelin debris clearance in the CPZ model [8]. Similarly,
lack of TREM2 in AD experimental models led to reduced
microglia number, clustering and activation around CNS
amyloid plaques accompanied by decreased plaque compaction and increased neuritic damage [50, 51, 53]. In line with
these observations, TREM2 was demonstrated to mediate
the switch from a homeostatic to a disease-associated microglia (DAM) phenotype [21]. TREM2 on microglia may also
act as a lipid sensor capable of binding myelin debris with
subsequent engulfment and clearance [42]. Our data demonstrate that AL002a is a potent TREM2 agonist antibody
capable of activating TREM2 in vitro and in vivo and to
potentiate myelin-induced activation of TREM2 signaling.
We further characterized the role of AL002a in the in vivo
model of CPZ-induced CNS demyelination. First, we tested
AL002a in Trem2+/+ mice, without detecting any difference
in damaged myelin accumulation, number of microglia or
OPC in the CC compared to the control group at 4 weeks on
CPZ (data not shown). These results were not unexpected
given the rapid microglia response to damage, efficient
clearance of myelin debris and subsequent remyelination
after CPZ in wild-type mice [17]. Next, we tested AL002a
in Trem2+/− mice, which had less efficient clearance of
damaged myelin compared to their wild-type counterparts,
giving us the opportunity to unveil any effect of antibodymediated TREM2 activation on CPZ-induced pathology.

Indeed, AL002a treatment in vivo significantly enhanced
myelin debris clearance in Trem2+/− mice compared to the
control Trem2+/− group. This was likely due to a direct effect
of AL002a on microglia, which consistently was shown to
express TREM2 [45]. AL002a treatment in vivo by activating TREM2-dependent intracellular pathways led to more
efficient myelin phagocytosis and degradation by microglia.
This was accompanied by increased microglia expression of
markers of activation (Iba1 and CD80) and phagolysosomal
activity (CD68 and LAMP1). Similar effects were observed
in BMDM in vitro. Our results clearly suggest that TREM2
plays a key role in myelin engulfment and intracellular processing by microglia. TREM2 has often been referred to as
a phagocytic receptor as it was demonstrated to be involved
in microglia phagocytosis of apoptotic neurons [46], myelin
[8] and β-amyloid [24]. However, our current and previous
findings indicate a more complex TREM2 function not only
in myelin uptake, but also in promoting myelin debris degradation through the phagolysosomal pathway [8]. These findings were corroborated by the analysis performed in macrophages derived in vitro from NHD patients revealing that
genes involved in the phagosome pathway are significantly
altered in NHD subjects compared to healthy controls along
with changes in immune response pathways. Therefore, myelin and axonal degeneration observed in NHD underscore a
critical function played by microglia and TREM2 in myelin
clearance, phagocytic functions, and maintenance of neuronal integrity.
We have previously reported that Trem2−/− mice have a
significant defect compared to Trem2+/+ in microglia numbers and proliferation at 4 weeks on CPZ and this could
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Fig. 9  Phagocytic pathways dysregulation in macrophages derived
from individuals affected by Nasu–Hakola disease. a Heat map showing different expression patterns of genes in Nasu–Hakola (NHD)
patients and healthy controls (CTR). The heat map indicates up-regulation (red) and down-regulation (green). b Gene ontology analy-

sis of the differentially expressed genes in NHD patients. c Volcano
plots showing the distribution of gene expression fold changes in
genes of the phagosome pathway. Genes with fold change > 2 and P
value < 0.05 are indicated in red, and genes with fold change < − 2
and P value < 0.05 are indicated in green

contribute to the defect in removing myelin debris from
the tissue [8]. Interestingly, in the current study at this
time point no differences in the number of microglia were
detected between Trem2+/− and Trem2+/+ mice, despite more
myelin debris were accumulating in the CC of Trem2+/−.
This could suggest that one copy of TREM2 is sufficient to
sustain microglia expansion after CPZ-induced damage, but
cannot support a fully functional response by microglia to
clear the conspicuous amount of myelin debris derived from
massive oligodendrocyte death. Alternatively, it is possible
that a defect in microglia proliferation in Trem2+/− mice is
present, but at earlier time points (before 4 weeks) and in a

very narrow time window. To this end, a very robust microglia activation and increase in density have been shown to
start at 2–3 weeks after CPZ diet initiation, reaching a plateau at 4–5 weeks [15]. Future studies are needed to clarify
if TREM2 activation could also directly enhance microglia
proliferation in vivo.
TREM2 has been described to be intimately linked to
microglia lipid metabolism [8, 42]. Lipids have been proposed as candidates for TREM2 ligands either as free molecules, complexed in myelin or in apolipoprotein particles
[1, 2, 42, 50]. A recent report demonstrated that TREM2 is
highly expressed in the adipose tissue by lipid-associated
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macrophages (LAM) where it drives gene expression programs involved in phagocytosis and lipid metabolism [19].
LAM cells in adipose tissue indeed expressed a highly similar gene profile as disease-associated microglia in AD with
the exception of few tissue-specific genes [19, 21]. Chronic
demyelination in vivo (12 weeks on CPZ) caused a robust
accumulation of cholesteryl ester (CE) and oxidized CE in
the Trem2−/– brain, suggesting that TREM2 might be a crucial transcriptional regulator of cholesterol transport and
lipid metabolism in microglia [35]. In support of a strong
link between TREM2 and lipid metabolism are also the original reports describing NHD as a lipid storage disease due to
a genetic enzymatic defect leading to lipid and cholesterol
accumulation in the brain and bone cysts [37]. Therefore,
it is attractive to suggest that a major role for TREM2 in
microglia would be intracellular processing and degradation of lipid-rich material (e.g. myelin, cell membranes),
especially after extensive demyelination. In our previous
work, we provided initial evidence to support this hypothesis
by showing that TREM2 is not a limiting factor in myelin
engulfment, but it was clearly essential for microglia capacity to degrade myelin during chronic demyelination [8]. In
the current study, we further support this hypothesis and
we expand by showing that AL002a treatment significantly
increases microglia capacity to phagocyte and degrade myelin in vivo and in vitro. These results confirm TREM2 as a
key regulator of phagocytic clearance of myelin debris and
lipid metabolism by microglia.
The identification of therapies promoting remyelination
is a new frontier to overcome in MS. Approved diseasemodifying treatments for MS are targeting the inflammatory disease component by reducing attack frequency and
severity. Currently, no therapies are available to regenerate
myelin and to halt MS disease progression. In MS multiple
factors are thought to be involved in remyelination failure,
starting with a deficiency in OPCs because of impaired
recruitment, or incomplete differentiation and maturation
in the MS lesions. Several lines of evidence indicate a key
role of microglia in these processes. Microglia regenerative expression profile involves genes related to phagocytosis, breakdown of myelin debris, as well as secretion of
regenerative factors and tissue remodeling [36, 49] that
can drive OPC differentiation [29, 32]. Here we show that
TREM2 was highly expressed within active MS lesions by
lipid-laden microglia/macrophages known to display an
alternatively activated M2 profile and to promote the resolution of inflammation and clearance of myelin debris [5].
AL002a, by targeting and activating mouse TREM2, seems
to enhance some of these pathways. It is not fully clear if
enhanced remyelination in AL002a-treated Trem2+/− mice
is due to accelerated removal of myelin debris or if there is
an additional TREM2-mediated signal from the microglia
to recruit OPCs, thus giving an advantage in remyelination.
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Successive studies will further clarify potential microglia
polarization or remodeling induced by AL002a. On the other
end, it is well known that Trem2+/+ mouse microglia are very
efficient in supporting complete remyelination in the acute
CPZ model. This is different from what observed in MS,
where a defect in TREM2 pathways has not been demonstrated, but still remyelination fails in most cases. A possible
hypothesis could be that, in MS, microglia are chronically
challenged by recurring bouts of demyelination and remyelination, suggesting that they might become exhausted and
less able to respond over time. In this situation, microglia
could be more responsive to an increase in TREM2 signaling via antibody-mediated activation. In future studies we
could examine this further by either chronically feeding CPZ
or looking in aged mice in which microglia functions could
be defective.
Importantly, our study has also shown that AL002a treatment after CPZ is associated with reduced Nf-L plasma levels (a markers of axonal/neuronal damage), suggesting that
increased remyelination also results in preserved axonal integrity, further proven by increased SMI31 staining in the CC of
AL002a-treated mice. Altogether our study indicates that strategies aimed at targeting TREM2 on microglia in the CNS are
feasible and might be a promising intervention in MS to promote microglia functions in clearing myelin debris, favoring
the recruitment of OPCs, and their subsequent differentiation
into mature myelin-generating oligodendrocytes, eventually
leading to remyelination and axonal protection.
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